Chelsea Therapeutics

Chelsea Therapeutics International

Company: Chelsea Therapeutics International, Ltd. Status: Acquired by Lundbeck (2014) Headquarters: Charlotte, North Carolina, USA (previously) Founded: 2004 Acquired by: H. Lundbeck A/S (June 2014, ~$658M deal)

Overview

Chelsea Therapeutics International

Company: Chelsea Therapeutics International, Ltd. Status: Acquired by Lundbeck (2014) Headquarters: Charlotte, North Carolina, USA (previously) Founded: 2004 Acquired by: H. Lundbeck A/S (June 2014, ~$658M deal)

Overview

Chelsea Therapeutics International was a biopharmaceutical company focused on the development and commercialization of products for the treatment of neurogenic orthostatic hypotension (nOH) and other disorders affecting the autonomic nervous system. The company's flagship product, [Northera (droxidopa) for neurogenic orthostatic hypotension](/therapeutics/droxidopa), received U.S. Food and Drug Administration (FDA) approval in 2014 for the treatment of symptomatic nOH, making it the first FDA-approved therapy for this indication["@droxidopa-fda"].

Chelsea Therapeutics was acquired by [H. Lundbeck A/S](/companies/lundbeck) in June 2014 for approximately $658 million, adding a critical product to Lundbeck's neuroscience portfolio while expanding into autonomic medicine["@droxidopa-chelsea"].

Technology Platform

Droxidopa (Northera)

Mechanism of Action:

Droxidopa is a synthetic amino acid that serves as a prodrug of [norepinephrine](/entities/norepinephrine). Upon oral administration, droxidopa is converted to norepinephrine by the enzyme aromatic L-amino acid decarboxylase (AADC). This conversion occurs both in the periphery and in the CNS, allowing droxidopa to restore deficient norepinephrine levels in patients with autonomic failure[@northera-label].

Pharmacology:

• Acts as a prodrug: absorbed as droxidopa, converted to norepinephrine
• Restores sympathetic tone lost due to autonomic neuropathy
• Improves orthostatic tolerance through vasoconstriction and increased cardiac output
• Does not cross the blood-brain barrier significantly (peripheral conversion predominant)

The development program for droxidopa included multiple Phase 3 clinical trials demonstrating:

Clinical Trials:

| Trial | Phase | Population | Primary Endpoint | Result |
|-------|-------|------------|------------------|--------|
| NOH301 | Phase 3 | nOH (PD, PAF, diabetic neuropathy) | OHQ change from baseline | Positive |
| NOH302 | Phase 3 | nOH refractory to midodrine | OHQ, BP maintenance | Positive |
| NOH306 | Extension | Long-term safety | Safety/tolerability | Ongoing post-approval |

Orthostatic Hypotension in Parkinson's Disease

Patients with [Parkinson's disease](/diseases/parkinsons-disease) frequently develop neurogenic orthostatic hypotension due to:

• Cardiac sympathetic denervation: Loss of postganglionic sympathetic neurons
• Impaired baroreflex sensitivity: Reduced compensatory responses to positional changes
• Medication effects: Levodopa and dopamine agonists can worsen OH
• Alpha-synuclein pathology: Lewy body accumulation in autonomic neurons[@gibbons2019]

Product Portfolio

Northera (Droxidopa)

| Attribute | Details |
|-----------|---------|
| Brand Name | Northera |
| Generic Name | Droxidopa |
| Formulation | Oral capsules (100 mg, 200 mg, 300 mg) |
| Indication | Symptomatic neurogenic orthostatic hypotension |
| Approved Populations | Parkinson's disease, Multiple System Atrophy, Pure Autonomic Failure, Diabetic neuropathy |
| Dosing | 100-600 mg TID (three times daily) |
| FDA Approval Date | August 2014 |
| Schedule | Not scheduled (not a controlled substance) |
| Manufacturer | Lundbeck (post-acquisition) |

Efficacy in PD-Specific Studies:

Clinical trials specifically enriched for PD patients showed:

• Mean increase in systolic BP at 1 minute standing: ~15-20 mmHg vs. placebo
• Clinically meaningful improvement in dizziness (92% vs. 76% in placebo group)
• Reduction in fall risk associated with syncope

• Common: Headache, dizziness, nausea, hypertension (supine)
• Serious: Supine hypertension (requires bedtime dosing restriction), potential for cardiac arrhythmias
• Monitoring: Supine blood pressure monitoring required; avoid supine position for 2-3 hours after dosing

Lundbeck Acquisition

Deal Structure

In June 2014, Lundbeck acquired Chelsea Therapeutics for approximately $658 million, representing a 72% premium over Chelsea's closing stock price at the time.

Strategic Rationale for Lundbeck:

• Added FDA-approved product with strong differentiation in nOH
• Expanded into autonomic dysfunction — aligned with Lundbeck's CNS focus
• Established base in US specialty pharmaceutical market
• Droxidopa provided recurring revenue stream to fund pipeline investments

• Lundbeck commercialized Northera in the US market
• Expanded indication development (investigating PD-specific formulations)
• Integrated into Lundbeck's existing neurology sales infrastructure

Impact on PD Autonomic Dysfunction Treatment

Northera's approval represented a significant advance in the treatment of orthostatic hypotension in PD:

The availability of droxidopa also enabled combination therapy approaches:

• With midodrine: Sequential or concurrent use for refractory OH
• With fludrocortisone: For patients requiring additional volume expansion
• With physical countermeasures: Compression stockings, head-of-bed elevation

Related Pages

Disease and Mechanism Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autonomic Dysfunction in Parkinson's Disease](/mechanisms/parkinsons-autonomic-dysfunction)
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
• [Norepinephrine Signaling](/mechanisms/norepinephrine-signaling)

Treatment Pages

• [Droxidopa (Northera) Therapeutic Profile](/therapeutics/droxidopa)
• [Orthostatic Hypotension Treatments](/therapeutics/orthostatic-hypotension-treatments)
• [PD Non-Motor Symptom Treatments](/therapeutics/parkinsons-non-motor-symptoms)

Company Pages

• [H. Lundbeck A/S](/companies/lundbeck)
• [PD Autonomic Dysfunction Treatment Companies](/companies/pd-autonomic-dysfunction-treatments)

References